COMPARISON OF MAMMAPRINT VERSUS ONCOTYPE DX IN PREDICTING RISK OF BREAST CANCER RECURRENCE alexis.knutson@unlv.edu

PW04-01

COMPARISON OF MAMMAPRINT VERSUS ONCOTYPE DX IN PREDICTING RISK OF BREAST CANCER RECURRENCE

2

 

 

 

 

United States

Poster with Discussion

Gene expression profiling tools such as MammaPrint and Oncotype DX, introduced in the early 2000s, help identify high-risk genotypic variants to risk stratify women with breast cancer. Ongoing discussions focus on when to use each tool and which patients would benefit most. This project compares the use of MammaPrint versus Oncotype DX in women with hormone receptor-positive breast cancer, their ability to stratify recurrence risk, and the utility of these recurrence scores in predicting response to hormone therapy and chemotherapy.

Review of recent studies (MINDACT, TailorX trials) evaluating the benefit of molecular diagnostic tools such as Mammaprint and Oncotype DX on risk stratification, chemotherapy benefit, and recurrence risk in women with breast cancer.

For women with intermediate recurrence scores, TailorX revealed endocrine therapy alone is non-inferior to combined chemo-endocrine therapy. According to the MINDACT trial, women with early-stage breast cancer with high clinical risk but low genomic risk for recurrence might not require chemotherapy.

Both OncotypeDX and Mammaprint are effective for prognostication in hormone receptor positive, HER2- breast cancer. OncotypeDX may be preferred for predicting chemotherapy benefit in patients with intermediate recurrence scores whereas MammaPrint may be more helpful in distinguishing between high vs low risk for recurrence, both clinically and genomically. It's unclear whether a low-risk Oncotype or low/ultra-low-risk Mammaprint score can justify discontinuing hormonal therapy entirely. While MammaPrint and Oncotype DX each have their advantages, perhaps using both synergistically can help tailor the best treatment plan for each unique patient.